Sugi Predict

Sugi Predict / Compounds / SCHEMBL405823

SCHEMBL405823

SCHEMBL405823

CNNc1ncnc2nc[nH]c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 6/20 0.58
▸ CYP1A2 P05177 3/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ CYP3A4 P08684 1/20 0.54
▸ LMNA P02545 6/20 0.54
▸ PAK1 Q13153 1/20 0.53
▸ CDK2 P24941 2/20 0.53
▸ HSD17B10 Q99714 4/20 0.51
▸ PKM P14618 1/20 0.51
▸ MKNK1 Q9BUB5 1/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ PRMT1 Q99873 1/20 0.51
▸ TSHR P16473 3/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ RECQL P46063 1/20 0.49
▸ BRAF P15056 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29380490 0.85 HTT (0.62) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL21914 0.85 HTT (0.62) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL6243538 0.83 HTT (0.60) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL10918760 0.83 HTT (0.60) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL11591794 0.79 HTT (0.59) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL160074 0.77 CYP3A4 (0.62) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL1095418 0.77 CYP1A2 (0.60) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL9116347 0.77 HTT (0.57) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL17901710 0.77 HTT (0.57) HTTCYP1A2HIF1ACYP3A4LMNA
SCHEMBL29420373 0.77 CYP3A4 (0.62) HTTCYP1A2HIF1ACYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4740951-A2 IGH REARRANGEMENTS AND USES THEREOF Foundation Medicine, Inc. (US) 2026-05-13 — — EP disclosed
EP-4267767-B1 IGH REARRANGEMENTS AND USES THEREOF FOUND MEDICINE INC (US) 2026-04-01 — — EP disclosed
US-20250378926-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2025-12-11 — — US disclosed
US-20250340615-A1 NOVEL FUSION MOLECULES AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2025-11-06 — — US disclosed
US-20250333479-A1 NOVEL FUSION MOLECULES AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2025-10-30 — — US disclosed
US-20250333480-A1 FUSION MOLECULES AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2025-10-30 — — US disclosed
US-12378302-B2 Fusion molecules and uses thereof FOUNDATION MEDICINE, INC. (US) 2025-08-05 — — US disclosed
US-20240360199-A1 NOVEL FUSION MOLECULES AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2024-10-31 — — US disclosed
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2024-02-29 — — US disclosed
EP-4267767-A1 IGH REARRANGEMENTS AND USES THEREOF Foundation Medicine, Inc. (US) 2023-11-01 — — EP disclosed
US-20100272721-A1 TREATMENT OF CANCER BIOGEN IDEC MA INC. (US) 2010-10-28 — — US disclosed
US-20100113294-A1 DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS MOMENTA PHARMACEUTICALS, INC. (US) 2010-05-06 — — US disclosed
CN-101681396-A Glucoprotein product that limits and associated method MOMENTA PHARMACEUTICALS INC 2010-03-24 — — CN disclosed
EP-2137655-A1 DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS Momenta Pharmaceuticals, Inc. (US) 2009-12-30 — — EP disclosed
US-20080292622-A1 METHODS OF EVALUATING PATIENTS BIOGEN IDEC MA INC. (US) 2008-11-27 — — US disclosed
US-20080279853-A1 TREATMENT OF CANCER BIOGEN IDEC MA INC. (US) 2008-11-13 — — US disclosed
WO-2008128230-A1 REFERENCE GLYCOPROTEIN PRODUCTS AND RELATED METHODS MOMENTA PHARMACEUTICALS, INC. (US) 2008-10-23 — — WO disclosed
WO-2008128227-A1 DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS MOMENTA PHARMACEUTICALS, INC. (US) 2008-10-23 — — WO disclosed
WO-2006138219-A2 METHODS OF DIAGNOSIS / PROGNOSIS OF INFLAMMATORY CONDITIONS BIOGEN IDEC MA INC. (US) 2006-12-28 — — WO disclosed
WO-2006130429-A2 TREATMENT OF CANCER BIOGEN IDEC MA INC. (US) 2006-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250378926-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 HTT 541/4885CYP1A2 4813/4885HIF1A 1724/4885
US-20250340615-A1 NOVEL FUSION MOLECULES AND USES THEREOF RPS27A, CD2BP2, FGB HTT 4166/4885CYP1A2 4879/4885HIF1A 2404/4885
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS MKI67, BRCA1, CLN6 HTT 541/4885CYP1A2 4813/4885HIF1A 1724/4885
US-20240360199-A1 NOVEL FUSION MOLECULES AND USES THEREOF RPS27A, CD2BP2, FGB HTT 4166/4885CYP1A2 4879/4885HIF1A 2404/4885
US-12378302-B2 Fusion molecules and uses thereof RPS27A, CD2BP2, FGB HTT 3724/4885CYP1A2 4879/4885HIF1A 2682/4885
US-20250333479-A1 NOVEL FUSION MOLECULES AND USES THEREOF RPS27A, CD2BP2, FGB HTT 4166/4885CYP1A2 4879/4885HIF1A 2404/4885
US-20250333480-A1 FUSION MOLECULES AND USES THEREOF RPS27A, CD2BP2, FGB HTT 3724/4885CYP1A2 4879/4885HIF1A 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.